Full Press Release Details
Oncolytics Biotech Inc. to Present at the Canaccord
Genuity 37th Annual Growth Conference
CALGARY, AB and SAN DIEGO, CA, Aug. 1, 2017 /CNW/ - Oncolytics
Biotech Inc. (Oncolytics or the Company) (TSX:ONC) (OTCQX:ONCYF) will present at the Canaccord Genuity 37th
Annual Growth Conference. The presentation, by Dr. Matt Coffey, President & CEO of Oncolytics, will take place at 9:00
am ET, on Thursday, August 10, 2017 in the Hong Kong Room at the Intercontinental Hotel. The conference takes place on August 9th
& 10th in Boston, MA.
A live audio link to the webcast session will be available
on the Company's website at http://www.oncolyticsbiotech.com/investor-centre/presentations. It is recommended that listeners log
on 10 minutes in advance of a live session to register and download any necessary software. An audio replay will be accessible
approximately two hours following the presentation on the Oncolytics website.
About Oncolytics Biotech Inc.
Oncolytics is a biotechnology company developing REOLYSIN , an immuno-oncology viral-agent, as a potential treatment
for a variety of tumor types. The compound induces selective tumor lysis and promotes an inflamed tumor phenotype through innate
and adaptive immune responses to treat a variety of cancers. Oncolytics' clinical development program emphasizes three pillars:
chemotherapy combinations to trigger selective tumor lysis; immuno-therapy combinations to produce adaptive immune responses; and
immune modulator (IMiD) combinations to facilitate innate immune responses. Oncolytics is currently planning its first registration
study in breast cancer, as well as studies in combination with checkpoint inhibitors and IMiD/targeted therapies in solid and hematological
malignancies. For further information about Oncolytics, please visit: www.oncolyticsbiotech.com.
This press release contains forward-looking statements,
within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements, including the
Company's belief as to the potential of REOLYSIN (pelareorep) as a cancer therapeutic; the Company's expectations
as to the success of its research and development programs in 2017 and beyond, the Company's planned operations, the value of the
additional patents and intellectual property; the Company's expectations related to the applications of the patented technology;
the Company's expectations as to adequacy of its existing capital resources; the design, timing, success of planned clinical trial
programs; and other statements related to anticipated developments in the Company's business and technologies involve known and
unknown risks and uncertainties, which could cause the Company's actual results to differ materially from those in the forward-looking
statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue research and
development projects, the efficacy of REOLYSIN as a cancer treatment, the success and timely completion of clinical studies and
trials, the Company's ability to successfully commercialize REOLYSIN, uncertainties related to the research and development of
pharmaceuticals, uncertainties related to the regulatory process and general changes to the economic environment. Investors should
consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information
on risks and uncertainties relating to the forward-looking statements. Investors are cautioned against placing undue reliance on
forward-looking statements. The Company does not undertake to update these forward-looking statements, except as required by applicable
SOURCE Oncolytics Biotech Inc.
View original content: http://www.newswire.ca/en/releases/archive/August2017/01/c6456.html
For further information: Oncolytics Investor & Media Contact:
Oncolytics Biotech Inc., Michael Moore, Vice President, Investor Relations & Corporate Communications, 858-886-7813, mmoore@oncolytics.ca
CO: Oncolytics Biotech Inc.
CNW 07:00e 01-AUG-17